CLPT stock forecast, quote, news & analysis
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain... Show more
Why ClearPoint Neuro (CLPT) Stock Is Down -31% in the Last 30 Days
Key Takeaways
- ClearPoint Neuro (CLPT) shares fell roughly 31% over the trailing 30 days, from about $13.83 to near $9.53.
- The sharpest single-day decline came on September 29, 2026, when the stock dropped about 23% after development partner uniQure (QURE) reported disappointing 48-month Huntington's disease trial data.
- The move largely reflects a repricing of the company's cell and gene therapy delivery optionality rather than a change in ClearPoint's reported operating results.
- ClearPoint's third-quarter 2026 financial results are scheduled for release on October 28, 2026, a key near-term catalyst.
- Several sell-side analysts have maintained Buy ratings while trimming price targets, and a shareholder law firm has announced an investigation (a solicitation notice, not a formal charge).
ClearPoint Neuro (CLPT) Company Overview and Market Position
ClearPoint Neuro, Inc. is a medical device company that describes itself as a "device, cell, and gene therapy-enabling" business offering precise navigation to the brain and spine. Its flagship product, the ClearPoint Neuro Navigation System, is FDA-cleared and CE-marked and is used by neurosurgeons to perform minimally invasive procedures under intra-procedural MRI guidance. The company also supplies disposable components such as SmartFlow cannulas used to deliver therapeutics directly into the brain.
Beyond its commercial neurosurgery products, ClearPoint partners with pharmaceutical and biotech companies, academic centers, and contract research organizations to support pre-clinical studies and clinical trials for central nervous system drug and gene therapy delivery. This dual model — established clinical products alongside drug-delivery services — is why investors follow the stock closely, particularly as a proxy for progress in cell and gene therapies targeting neurological diseases.
ClearPoint Neuro (CLPT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CLPT declined approximately 31%, moving from a closing price near $13.83 in mid-September to roughly $9.53. The decline was not gradual: the stock fell more than 23% in a single session on September 29, 2026, and continued to drift lower through October.
The broader quarterly picture is similar in direction but steeper in magnitude. Around mid-July, shares traded near $15.05, meaning the stock has lost roughly 37% over the trailing quarter. This multi-month downtrend reflects sustained pressure on the company's valuation tied to its drug-delivery partnership pipeline, compounded by a weaker backdrop for small-cap healthcare and medical device names.
What Drove CLPT Stock Price in the Last 30 Days
The dominant catalyst was a September 29, 2026 announcement from uniQure (QURE), ClearPoint's development partner. uniQure disclosed additional data from its Phase I/II studies of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease, noting the treatment did not achieve statistical significance on a primary clinical measure at 48 months. Because ClearPoint's platform is used to deliver that therapy into the brain, CLPT fell in sympathy, dropping 23.12% to $11.77 in that session.
ClearPoint issued no negative news of its own, and the company does not develop or own the drug. Nevertheless, investors had assigned meaningful value to the optionality of its gene therapy delivery partnerships, and the partner setback triggered a sharp repricing. Selling was reinforced in October after the law firm Pomerantz LLP announced it was investigating potential securities claims on behalf of investors — a standard solicitation notice that does not represent a formal charge or finding of wrongdoing.
What Drove CLPT Stock Performance Over the Last Quarter
The quarterly decline reflects a broader reassessment of ClearPoint's cell and gene therapy pipeline exposure. In March 2026, uniQure disclosed that the FDA indicated existing Phase I/II data were insufficient to support a marketing application and that a new randomized trial could be required — news that had already introduced uncertainty around the timing of potential commercialization through ClearPoint's delivery platform.
Fundamentally, the company's second-quarter 2026 revenue grew 18% year over year to $10.9 million, but results came in below Wall Street estimates, and management trimmed full-year 2026 guidance. Revenue in the biologics and drug delivery segment declined 15% on a non-recurring prior-year customer order, while growth was driven by neurosurgery navigation and the IRRAflow product line. These factors, together with broader pressure on speculative, unprofitable small-cap healthcare names, contributed to the sustained downward trend through October.
Trending AI Robots
Investors tracking volatility like ClearPoint Neuro's recent move often turn to quantitative tools for additional context. Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots drawn from a much larger universe of hundreds of bots trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, and each bot can differ meaningfully in strategy, trading timeframe, and performance metrics. The page is designed to help users explore automated approaches without prescribing any single one. For those seeking a data-driven perspective on market activity, reviewing the Trending AI Robots section can be a useful starting point.
CLPT Stock Forecast Drivers: What Investors Should Watch Next
The most immediate catalyst is ClearPoint's third-quarter 2026 earnings report, scheduled for October 28, 2026, where investors will look for updates on revenue growth, biologics segment demand, cash burn, and full-year guidance. Commentary on the status and timeline of partner cell and gene therapy programs — including any updates related to uniQure's regulatory path — is likely to be closely watched.
Beyond earnings, investors should monitor continued adoption of the ClearPoint navigation system and IRRAflow product line, progress at the company's pre-clinical services facility, and the trajectory of its cash position. Macroeconomic conditions, including interest rates and sentiment toward unprofitable small-cap healthcare equities, also remain relevant to the stock's valuation. These factors, rather than any single data point, are likely to shape the stock's path in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CLPT in upward trend: price may jump up because it broke its lower Bollinger Band on September 29, 2026
CLPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 36 cases where CLPT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLPT's RSI Indicator exited the oversold zone, 24 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in 216 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLPT as a result. In 80 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for CLPT turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 47 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
CLPT moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CLPT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (26.184) is slightly higher than the industry average of (2.923). P/E Ratio (-7.839) is within average values for comparable stocks, (2.388). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain and heart.
Industry MedicalNursingServices